Good Times Restaurants operates and franchises Bad Daddy's Burger Bar restaurants (Bad Daddy's) and Good Times Burgers & Frozen Custard (Good Times) restaurants. Bad Daddy's and Good Times are two distinctly different, yet complementary, restaurant concepts. Bad Daddy's operates in the casual dining segment of the restaurant industry. Bad Daddy's operates all of its company-owned restaurants under a table service / full-bar service model. The menu is comprised of burgers, salads, sandwiches, and appetizers. Good Times is a quick service restaurant concept offering hand crafted products. Good Times provides a menu of Angus beef and chicken.

Odonate Therapeutics is a pharmaceutical company focused on the development of therapeutics that improve and extend the lives of patients with cancer. The company's initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. In patients with metastatic breast cancer, tesetaxel was shown to have single-agent antitumor activity in two multicenter, Phase 2 studies. The company is conducting a multinational, multicenter, randomized, Phase 3 study in patients with locally advanced or metastatic breast cancer, known as CONTESSA.

Pulse Biosciences is a bioelectric medicine company. The company is pursuing regulatory clearance to market CellFX? System (CellFX). The CellFX System utilizes its Nano-Pulse Stimulation? (NPS) technology to treat various applications for which an optimal solution remains unfulfilled. NPS is a proprietary technology that delivers nanosecond duration pulses of high amplitude electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue. The company's CellFX System allows for the adjustment of four key treatment parameters: pulse duration, pulse amplitude, pulse frequency, and the number of pulses, depending on the target tissue, application and desired treatment outcome.

TRACON Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of targeted therapeutics for cancer and wet age-related macular degeneration. The company is developing its primary product candidate, TRC105 (carotuximab), an endoglin antibody, for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor pathway, or in combination with inhibitors of the programmed cell death protein 1 pathway. The company's second clinical stage product oncology candidate is TRC102, a small molecule being developed for the treatment of lung cancer and mesothelioma.